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Sj¨ ogren’s syndrome (SjS) is a chronic autoimmune disorder characterized by dry eyes and dry mouth due to dacryoadenitis and
sialoadenitis with SS-A/Ro and/or SS-B/La autoantibodies in genetically predisposed individuals. Destruction of lacrimal and
salivary glands by autoimmune reactions may lead to clinical manifestation. However, the mechanisms behind the decreased
volume of secretions in tears and saliva are complex and are not fully understood. Exocrine gland dysfunction may precede
autoimmunity (acquired immunity) or represent a process independent from inﬂammation in the pathogenesis of SjS. The
precededfunctionalandmorphologicchangesofthosetissuesbynonimmunologicinjurybeforethedevelopmentofinﬂammation
at the sites of target organs have been implicated. This paper focuses on the several factors and components relating to glandular
dysfunction and morphologic changes by nonimmunologic injury during the preinﬂammatory phase in mouse model, including
the factors which link between innate immunity and adaptive immunity.
1. GeneralIntroduction of SjS
1.1. pSjS and sSjS. Majority of patients with SjS are women,
and the diagnosis is usually done when they are 40–50 years
old [1]. SjS primarily aﬀects women and may occur as an
isolated disorder, which is termed as primary SjS (pSjS),
or it may occur in association with recognized collagen
diseases, such as rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), and other collagen diseases, termed as
secondary SjS (sSjS) [2, 3]. Although the clinical manifes-
tations of pSS patients are mainly those of an autoimmune
exocrinopathy,almosthalfofpatientsdevelopextraglandular
disease and confer increased risk (approximately 5% of
patients with pSjS) for lymphoma (B cell non-Hodgkin’s
lymphoma) development [4, 5]. pSjS involves muscular, res-
piratory, gastrointestinal, renal, hepatic, pancreatic, periph-
eral, central nervous, and lymphoid tissues [6, 7].
1.2. Triggering Factors in pSjS and sSjS
1.2.1. Gene. Like other autoimmune diseases, relationship
betweenHLAallelesandSjSpathogenesishasbeensuggested
[8, 9]. Polymorphisms of the interferon regulatory factor
5(IRF-5),ageneimplicatedintypeIIFNsecretionafterstim-
ulation of innate immunity and in type 1 IFN signal trans-
duction, are associated with disease susceptibility in pSjS
[10, 11]. Copy number variants of two relevant to immune
regulation genes such as Fcγ receptor 3B(FCGR3B) and CC
chemokine ligand 3-like 1 (CCL3L1) contribute to suscepti-
bility to autoimmune diseases such as SLE and pSjS [12].
1.2.2. Hormone. Hormonal unbalance may be one of the
major triggering factors behind the syndrome of SjS and the
increased risk is due to a change in the androgen–estrogen
ratio and sex steroids including lack of androgens inﬂuence
both at the systemic (fatigue) and local (exocrine glands)
level [13]. As the peak age of onset in SjS occurs around
menopause characterized by a decrease in estrogens, and
ovaries produce low levels of testosterone, which decrease
at the time of menopause [14, 15]. The other signiﬁcant
source of androgens is the adrenal cortex, which produces
dehydroepiandrosterone (DHEA) and its metabolite DHEA
sulfate (DHEA-S) [14, 15]. Other than the triggering
eﬀects of hormone, inﬂuence of androgens and pituitary
hormones on the structural proﬁle and secretory activity2 Journal of Biomedicine and Biotechnology
of the lacrimal gland has been suggested [16]. Tzioufas et
al. [17] reported that the hypothalamic-pituitary-adrenal
(HPA) axis appears to be disturbed, since signiﬁcantly lower
basal adrenocorticotropic hormone (ACTH) and cortisol
levels were found in patients with SjS. The hypothalamic-
pituitary-gonadal (HPG) axis is also involved, since lack
of estrogens is associated with human disease and the
developmentofautoimmuneexocrinopathyinseveralexper-
imental models. Moreover, exocrine glands are enriched
with neuroendocrine-related molecules. Psychological dis-
turbances can be very well explained by mechanisms directly
related to disturbances of the neuroendocrine axis. Apart
from functional changes, the syndrome is also characterized
bystructuralabnormalitiesofthesecretoryacinarapparatus,
and patients with SjS show low serum DHEA levels, which
may lead to acinar cell degeneration, and an autoimmune
attack directed against exocrine glands and nuclear autoanti-
gens may occur [18].
1.2.3. Pathogen. Among various environmental factors viral
infections may act as a trigger before the development of
inﬂammation [19] or may be involved during the process
of immune reactions [20]. Several viruses such as Epstein-
Barr virus (EBV; types 1 and 2) [21, 22] and hepatitis
C virus, retroviruses such as human T-cell lymphocytic
virus type 1 (HTLV-1) [23], and endogenous retroviruses
such as a HERV-K113 [24] have been found to be closely
associated with the patients with pSjS and sSjS. Also,
the incidence of keratoconjunctivitis sicca is increased in
patients with exogenous retroviruses like immunodeﬁciency
virus infection [25]. Expressed HERV-encoded proteins,
which would be considered as foreign antigens, result in
production of antibodies against them in patients. These
lead to cross-reaction with the components of the body
such as between ribonucleoprotein(Sm) and HERVs [20],
or between lipocalin/α-fodrin and EBV [26]v i as t r u c t u r a l
or functional molecular mimicry [27]. Also, bacteria can
activate innate immune responses interacting with Toll-
like receptors (TRLs) that recognize pathogen-associated
molecules, resulting in a prolonged inﬂammatory response
that may occur and lead to chronic inﬂammation with
activation of adaptive immune responses [27]. Alternatively,
some infectious agents such as malaria, Toxoplasma gondii,
and Helicobacter(H.) pylori may have a protective eﬀect
in SLE [27]. In contrast H. pylori may contribute to the
pathogenesis in SjS [28]. In addition, epidemiological and
experimental data suggest that infections or the exposure to
nonpathogenic bacteria protect individuals from developing
some autoimmune and atopic disorders [29].
1.3. Acquired Immunity in SjS
1.3.1. Cellular Immunity. A progressive loss of exocrine
gland function due to glandular damage is induced by
a lymphoid cell inﬁltration into these target organs. The
autoimmune character of the disease and diagnosis in
patients with SjS are made by focal lymphocytic sialoadenitis
in minor salivary glands with a focus score >1, deﬁned
as a number of lymphocytic foci (which are adjacent to
normal-appearing mucous acini and contain more than 50
lymphocytes per 4mm2 of glandular tissue) with positive
test for SjS autoantibodies (SS-A/Ro and SS-B/La) in the
serum [30]. Histopathology usually exhibits lymphocytic
inﬁltration, with the majority of lymphocytes being CD4+ T-
cells in the minor salivary gland lip biopsy from SjS patients
in accompanying B cells [5, 6, 31]. Inﬁltrated lymphocytes
a r ec o m p o s e do fm a i n l ya u t o r e a c t i v eC D 4 + T cells [32],
CD8+ T cells, and dendritic cells, and macrophages are
also present, and T cells preferentially express the T-cell
receptor (TCR)Vβ6a n dT C R V β8 in these tissues in an
animal model [33]. In human lymphocytes consisting of T
and B cells in the salivary gland lesions has been reported
[34, 35]. Various studies indicate that human minor salivary
gland biopsy tissue and salivary glands from mouse models
exhibited helper T(Th)1 type cytokine proﬁles at the sites
of target organs. For example, in labial salivary gland of
human patients with SjS interleukin (IL)-2 and interferon
(IFN)-γ mRNAs were consistently detected, whereas IL-4
and IL-5 mRNAs were detected in some cases associated
with strong B cell accumulation, suggesting Th1 cells are
essential in the induction and/or maintenance of SjS, while
Th2 cells are involved in the progression of the disease
process, especially in local B cell activation [36]. Moreover,
it has been reported that CD4+ T cells in salivary glands
expressedlargeamountsofIFN-γ mRNA,whereasthosecells
produced little IL-4 and IL-5 mRNAs in SjS patients [37].
Also lymphocytes inﬁltrating in the labial salivary glands of
patients with pSjS or sSjS are capable of producing both
Th1 and Th2 cytokines, and the balance between them
shifts in favor of Th1 responses in large salivary glands
with high inﬁltration score [38]. An increase in several
proinﬂammatory cytokines (mRNAs expression), including
interleukin(IL)-1β, tumor necrosis factor (TNF)-α,I L - 6 ,I L -
7, IL-10, IFN-γ, and inducible nitric oxide synthase (iNOS)
was demonstrated in the submandibular glands of nonobese
diabetes (NOD) mice, which are originally reported as a
model for insulin-dependent diabetes mellitus, a model for
pSjS with lymphocytic inﬁltrates [33]. Also, cytokine mRNA
detected in lacrimal tissue was similar to that seen in the
submandibular glands but appeared both earlier and more
intensely [33]. Distinct subset of CD4+ memory eﬀector T
cells such as Th17 cells may play an important in various
autoimmune diseases, including SjS [39–42]. Moreover, IL-
23/Th17 pathway has been implicated in SjS pathogenesis
in Ro52-null mice, which develops systemic autoimmune
disease resembling human lupus [43].
1.3.2. Humoral Immunity. Autoantibodies may also play
a role in the pathogenesis. Serologically, the presence of
rheumatoid factor, hypergammaglobulinemia, and antibod-
ies to nuclear protein, such as SS-A/Ro and SS-B/La [44]a s
well as antibodies against α-fodrin [45], carbonic anhydrase
II [46], and acetylcholine muscarinic3 receptor [47]h a v e
been observed in the sera of SjS patients. The later could play
a pivotal role in secretory function in pSjS [48]. In addition,
there is a possibility that cryptic antigens recognized by T
lymphocytes and antibodies in autoimmune pathogenesis
including SjS [49].Journal of Biomedicine and Biotechnology 3
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Figure 1: Hypothetical relationship between nonimmune (preinﬂammatory) phase and immune reaction (acquired immunity). Female
B/WF1 mice, a model for SLE and sSjS, develop several autoantibodies (e.g., anti-dsDNA and antinuclear antibodies: ANA) from younger
ages (approximately 12 weeks of age) and thereafter immune-complexes- (ICs-) mediated glomerulonephritis (GN) develops with age,
leading to overt disease (renal failure). On the other hand, production of anti-Ro/SS-A antibodies begin at the age of 20 weeks of age
and dacryoadenitis and sialoadenitis (SA/DA) may develop in salivary and lacrimal glands. During the nonimmune phase, abnormal
function and morphology of these tissues such endothelial cells (Ec) may permit leak of cytokines produced systemically. Dotted line shows
hypothetical functional defect. Green lines may indicate clinical manifestation (self-reported symptoms) in human patients with sSjS. In this
ﬁgure, the regenerative changes of acini components are not shown. T cell (T), B cell (B), and plasma cell (P).
2.Nonimmunologic Injuryin
PreinﬂammatoryPhase inSjS
2.1. Background. A number of references are increasing in
immune-mediated pathogenesis of SjS. On the other hand,
there are a few reports on nonimmunologic injury relating
to glandular dysfunction before inﬂammation. Although the
ﬂuid secretory impairment of lacrimal and salivary glands in
SjS is thought to be related to the extent of lymphocytic inﬁl-
tration and subsequent loss of glandular tissue, lymphocyte
inﬁltrationaloneisnotsuﬃcienttoexplainthesecretorydys-
function in the female NZB/W(B/WF1)m o u s e ,am o d e lf o r
sSjS and SLE, since less ﬂuid secretion in the young B/WF1
femalescomparedtoC57/6controlmicewasobservedbefore
the development of inﬂammation in lacrimal glands [50]
(Figures 1 and 2). Also, it has been suggested that the
decrease in salivary ﬂow follows the occurrence of focal
lymphoid inﬁltration, with a considerable delay in time,
and that the sole destruction or replacement of glandular
tissue by inﬂammatory cells is not suﬃcient to explain the
severe impairment in salivary secretion [51]. In addition,
Deshmukh et al. [52] reported that in the initial stages of the
disease gland dysfunction did not correlate with the severity
of lymphocytic inﬁltration/foci in the salivary gland and that
autoantibodies to salivary gland antigens or Ro60 may not
play a major role in the induction of gland dysfunction in
female B/WF1 mice. Jonsson et al. [51] indicated at least
2 phases of SjS-like disease in female NOD mice, where
hyposalivation was preceded by inﬂammatory changes in
the salivary glands, whereas abrupt changes in secretion
occurred without signiﬁcant progression of inﬂammation.
Moreover, submandibular gland histology revealed selective
loss of acinar tissue with decreased tear volume despite an
absence of sialoadenitis in NOD-scid mouse, which lacks T
and B cells [53]. Rosignoli et al. [54] reported a progressive
loss of nitric oxide synthase activity in submandibular and
parotid glands started at 12 weeks of age without inﬂamma-
tion and paralleled the decline in salivary secretion in NOD
mice, and this defect was associated with a lower response
to vasoactive intestinal peptide in salivary ﬂow rate, cAMP,
and nitric oxide/cGMP production. Their data suggest that
early stages are characterized by defective neurotransmitter-
mediated signaling in major salivary glands that precedes the
autoimmune response. In B/WF1 mice incomplete Freund’s
adjuvant accelerated glandular hypofunction, and this was
associated with sialoadenitis but without evidence of robust
adaptive autoimmune response in the early stages of the
disease [52].
2.2. Animal Model for Pathogenesis in SjS. As mentioned
above, the immunopathogenesis of SjS is complex with
diﬀerent intricate factors, including triggering factors such
as hormone, disease susceptibility gene especially major
histocompatibility complex (MHC), endogenous virus, and
exposure of cryptic antigens. Moreover, the delay in the
appearance of symptoms (self-reporting symptoms) and4 Journal of Biomedicine and Biotechnology
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Figure 2: Dysfunction of renal function due to glomerulonephritis may precede glandular dysfunction. Glomerulonephritis in diﬀerent
ages of female B/WF1 mice. Slight increase of mesangial cells (a), diﬀuse thickening of basement membranes with segmental proliferation
of mesangial cells (b), and sclerosing change (c) in glomeruli are visible. On the other hand, relatively normal structure in submandibular
gland is seen (d), but at this time dysfunction of glands is reported [50]. Focal lymphoid cell inﬁltration (e), and dense inﬁltration (f) are
visible. Samples were obtained survived mice (a, b, d, and e), whereas those were from dead mice (c and f). HE:(a–d). Azan: (e) and (f).
due to ethical issues, it is very diﬃcult to study the wide
array of factors interaction in the pathogenesis (especially
nonimmunologic injury) of SjS in human patients [31].
To solve this problem, diﬀerent animal models have been
elaborated for studying the diﬀerent subsets of the aspects
of the physiopathology of this disease. This review focused
on nonimmunologic injury before the development of
inﬂammation(acquiredimmunity)atthesiteoflacrimaland
salivary glands in relation with glandular dysfunction.
3. Discussion of PreviousResearch in SjS
Apoptosis, nonapoptosis, and abnormal distribution/expre-
ssion of aquaporin before the inﬂammation will be intro-
duced. Eﬀects of systemic factors (IFN-α [55], complement,
and cytokines) on components of target organs (autonomic
nerve, tight junction and basement membrane) due to
nonimmunologic injury will be also included (Figure 3).
Hormonal eﬀects on glandular function is stated in the
section of basement membrane.
3.1. Apoptosis. Classically, the pathogenesis of SjS proposed
in explaining glandular hypofunction is a two-step mech-
anism. At ﬁrst, a primary immune attack by inﬁltrating
lymphocytes and at second cytotoxic cell death (necrosis)
and apoptosis, which may be one of factors relating with
dysfunction of salivary and lacrimal glands, in genetically
predisposed individuals may occur [56]. In this section,
some reports of apoptosis induced probably by genetic
abnormality including the role of apoptosis as initiator willJournal of Biomedicine and Biotechnology 5
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Figure 3: Probable factors and causes (?), which may aﬀect function and structure in lacrimal and salivary glands in nonimmune injury
(Hypothesis). Environmental factors (especially viruses and bacteria) may play a role in both nonimmune and immune mechanisms. Self-
reporting symptoms in patients with SjS may be the results of cumulative eﬀects of nonimmune and immune mechanisms. Apart from
functional changes, the syndrome may be also characterized by structural abnormalities of microenvironmental components (niche) which
include endothelial cells (Ec) in capillary, myoepithelium (Me), nervous ﬁbers (An), basement membranes (Bm), tight junction (Tj), duct
(De), and secretory acinar epithelial cells. In addition, dendritic cells (Dc), which appear in pSjS patients but not in healthy controls [55],
mayplayanimportantroleinimmuneattacktogetherwitheﬀectors(E).Eﬀectofcirculatingcytokine∗ andgene∗ innonimmunephaseand
role of locally produced cytokine∗∗ and abnormal gene∗∗ being responsible for destruction of self-torerance in immune phase are indicated.
In this ﬁgure, detailed immune mechanisms including the role of environmental factors are omitted. E:e ﬀector cells (e.g., cytotoxic T cell,
Th1 cell, B cell, and plasma cell).
be introduced. Also, opposite opinions against apoptosis in
general pathogenetic roles are included.
It has been demonstrated using NOD mice and NOD-
scid (immunodeﬁcient) mice that the pathogenesis of SjS
occurs in two phases: an asymptomatic phase epithelial cells
of exocrine tissues undergo dediﬀerentiation accompanied
by elevated apoptosis and a second phase in which autoim-
munity is mounted against target organ autoantigens, result-
ing in the activation of T- and B-cells, and the generation of
autoantibodies [32]. Humphreys-Beher et al. [57]r e p o r t e d
that genetic alterations in glandular homeostasis involving
the death program may contribute to disease progression
or even in the initial trigger of autoimmunity, since there
are high levels of apoptosis and aberrant protein expression
in the submandibular gland in the absence of an immune
response in NOD mice. Kong et al. [58] demonstrated that
apoptosis of the secretory epithelial cells occurs in both
NOD and NOD-scid mice in salivary and lacrimal glands
in which Fas protein and mRNA were expressed only in the
exocrine glands before inﬂammation in NODand NOD-scid
mice, but not in normal BALB/c mice. A potential apoptotic
process dependent on Fas/Fas ligand (FasL) interactions
occurring in NOD-scid glandular secretory epithelial cells
strongly suggests the apoptosis may precede lymphocytic
inﬁltration [58]. Qi et al. [59] reported that apoptosis may
be initiator of inﬂammation in target organs in which
lacrimal dysfunction was found in the early age without
inﬂammation in NOD mice, and apoptotic cells exist in
acinar epithelium at 5 weeks of age, but not 2 weeks of
age without inﬂammatory foci in submandibular glands. If
that is the case, apoptosis may be induced genetically as
well as immunologically. The relationship between apoptosis
and dysfunction of glands in NOD-scid mice is unclear.
Apoptosis before inﬂammation in human SjS is not known.
3.2.Nonapoptosis. Apoptosisoftheepithelialcellsinthesali-
vary glands has been shown to be a rare event [60]. Many
patients with SjS who have little or no glandular function
(as evidenced by markedly diminished or absent saliva out-
put) retain large amounts of normal-appearing acinar tissue
in their salivary glands [61]. This residual tissue is functional
in vitro [62, 63], although they show a reduced sensitivity
to muscarinic stimulation [63]. Van Blokland et al. [64]
reported that before and after the onset of sialoadenitis
in NOD and NOD-scid mice, numbers of apoptotic cells
were not increased as compared with control mice at
any age. Expression of B-cell leukemia/lymphoma-2(bcl-2),
which is known as an antiapoptotic molecule by prohibiting
cytochrome c release from mitochondria and neutralizing
the function of apoptosis inducer Bax [65] on submandibu-
larglandepithelialcellsasearlyas3daysofageincreased,and
low-level expression of Fas and FasL mRNA was observed in
NOD and NOD-scid mice from 1 day of age onward [64].
Nonapoptosis mechanisms before inﬂammation do not deny6 Journal of Biomedicine and Biotechnology
the role of apoptosis during the process of inﬂammation,
since there are a number of references that apoptosis may
play an important role in the pathogenesis of SjS [66], but
there is a possibility of non-apoptotic mechanisms during
the process of the disease.
Using a non-apoptotic model for glandular hypofunc-
tion, Dawson et al. [66] have suggested that interaction bet-
ween the immune system and the secretory process could
lead to glandular hypofunction such as inhibition of neu-
rotransmitter release by cytokines, enhanced breakdown of
ACh by increased levels of cholinesterase, blockade of M3R
by antimuscarinic autoantibodies, and altered expression or
distribution of aquaporin5.
3.2.1. Aquaporin. Fundamental importance of aquaporins
by their conservation from bacteria through plants to mam-
mals has been suggested, and ten mammalian aquaporins
(AQPs) identiﬁed are expressed in several organs (e.g., the
kidney, lung, eye, and brain) and multiple water-channel
proteins that regulate the movement of water through
the plasma membrane of secretory and absorptive cells in
response to osmotic gradients [67]. Homologs are expressed
in each with a distinct distribution, providing a network
for water transport in those locations [67]. In this section,
at ﬁrst normal distribution/expression of AQPs in healthy
humanandanimalswillbementioned.Alsoabnormaldistri-
bution/expression of AQPs from human SjS, who may have
inﬂammation, and then data from mice will be introduced.
Abnormal distribution and expression of AQP5 in acini
of salivary glands are likely to contribute to the deﬁciency of
ﬂuid secretion during the noninﬂammatory phase but also
during the immunologic phase. Delporte [68] reviewed the
normal presence of AQP1(apical and basolateral membranes
of endothelium and myoepithelium of rat and human),
AQP3 (basolateral membranes of acinar in human), AQP4
(basolateral membranes of duct in rat), AQP5 (apical
membranes of acinar in rat and human, basolateral in acinar
or secretory granules in rat), AQPs 6 and 7(unknown),
and AQP8 (cytoplasm of myoepithelium in rat) in salivary
glands. Recently, it has been reported in more details that
AQP5 appeared mainly at the apical membrane of mucous
glands, basolateral membrane, and basal membrane of
serous acini including intense staining in the intercalated
ducts, striated ducts, and secretory ducts of the labial gland
in healthy volunteers, whereas AQP5 was distributed at
the basal membrane and obviously reduced at the apical
membrane in patients with SjS [69] .T h ep r e s e n c eo fA Q P 1 ,
AQP5, and AQP8 has been generally accepted by many,
while the presence of AQP3, AQP4, AQP6, and AQP7 still
remains controversially [68]. Among AQPs, AQP5 seems
to be the only AQP playing a major role in the salivary
secretion process and its expression was higher at the basal
membrane, and lower at the apical membrane of acinar
cells of salivary gland in pSjS [70]. In contrast, AQP5 is
normally present in the apical membrane of acinar cells,
whereas expression of AQP-1 in myoepithelial cells, but
not in endothelial cells of capillaries, was decreased by 38%
in pSS glands. Patients with pSjS or sSjS showing high %
reactivity of acinus area with AQP5 revealed AQP5 primarily
at the basal membranes of the acinus, whereas in patients
with low% of acinus area AQP5 was detected at the apical
membrane of acinar cells of salivary gland in patients with
pSjS [71]. Tsubotaet al.[72] reported cytoplasmic AQP5 was
seen in patients with SjS. Beroukas et al. [73] reported that
in patients with pSjS density of AQP5 in salivary glands does
not diﬀer between patients with pSjS and normal controls.
This discrepancy in human might be because of diﬀerences
between salivary and lacrimal glands, between populations
of patients [54], between pSS and sSS, or between diﬀerent
disease stages. Groneberg et al. [74] suggested that tissue-
speciﬁc diﬀerences, or diﬀerent techniques might aﬀect the
results. Abnormal distribution/expression of AQP5 in acinar
epithelium of minor salivary glands lacking inﬂammatory
cell inﬁltration was observed, suggesting that their abnormal
expression may not be due to only direct inﬂammatory cell
r e a c t i o n ,e v e ni nt h ei n ﬂ a m m a t o r yp h a s e[ 68].
By the comparative study between AQP+/+ mouse and
AQP5 knockout (AQP5−/−) mouse AQP5 was localized
mainly in the ductal cells rather than in the acinar cells of
the lacrimal gland without decreased tear secretion, whereas
in the parotid gland AQP-5 was observed abundantly in
acinar cells, but not in ductal cells, with reduced saliva
secretion [75]. In addition, Krane et al. [76] reported that
water permeability decreased by 65% in parotid and 77%
in sublingual acinar cells from AQP5−/− mice in response
to hypertonicity-induced cell shrinkage and hypotonicity-
induced cell swelling. These data show that AQP5 is the
major pathway for regulating the water permeability in
parotid and sublingual acinar cells (a critical property of
the plasma membrane which determines the ﬂow rate and
ionic composition of secreted saliva). Moore et al. [77]
provided the evidence that AQP5 in the apical membranes
of acinar and duct cells, AQP3 and AQP4 in the basolateral
membranes of acinar cells, and AQP1 in microvascular
endothelialcellsinlacrimalglandsintransgenicmicelacking
water channels AQPs. No decrease in tears in knockout mice
lacking AQP1, AQP3, AQP4, and AQP4 against an essential
role for AQPs in lacrimal gland secretion was observed
[77]. Soyfoo et al. [78] reported that the 8-week-old female
NOD mice without inﬂammation and normal age-matched
BALB/c(normal) mice showed a similar distribution of
AQP5 primarily at the apical membrane of the salivary
gland acini, whereas in acini from the submandibular glands
(but not from the parotid glands) from 24-week-old NOD
mice with inﬂammation, AQP5 staining was reduced at the
apical membrane but was increased at the basal membrane
compared to normal mice, in which a signiﬁcant decrease
in pilocarpine-stimulated salivary ﬂow was observed. On
the other hand, Nishimura et al. [79] reported that AQP-
5 was expressed in the apical and lateral cell membranes
of acinar cells in the parotid and submandibular glands of
normal mice, but not in the sublingualglands, whereasAQP-
5 was expressed not only in the cell membranes of acinar
cells in the apical domains but also in the cytoplasm in
the female MRL/lpr mouse, a model for not only RA-like
disease but also sSjS in human. There are some diﬀerences in
distribution/expression of AQPs. Thus, it has been pointed
out that the hypothesis that AQP5 has a major role in theJournal of Biomedicine and Biotechnology 7
pathogenesis of pSS needs to be reassessed and unconﬁrmed
issue has to be determined [80].
However, accumulating evidence suggests that abnormal
AQP5 expression/distribution in acini epithelium of salivary
(especially submandibular) glands, at least, may contribute
to hyposalivation at some extent before inﬂammation.
3.3. Type I Interferon (IFNα/β). Role of cytokines will be
mentioned later, but Type I IFN will be introduced in
this section from the point of innate immunity before the
development of immune reaction. Regarding the role of type
I IFN, studies in human SjS are relatively well done.
Current trends in autoimmune diseases are focusing
on innate immunity, which acts as a trigger on multiple
autoimmune diseases [19] .T y p eII F Nw i l lb ep r o d u c e d
as a consequence of the development of innate immunity.
High values of type I IFN are rapidly produced in viral
infection [81], but also in autoimmune diseases such as SLE
[82] .S e r u ml e v e l so ft y p eII F Nw e r ef o u n dt ob eh i g hi n
pSjS patients compared with normal individuals reported
by some groups [83, 84], but not by others [85]. Other
than role of type I IFN, the central role of B cell-activating
factor (BAFF), which promotes B-cell survival and exists in
a membrane bound and a secreted form, has been reported
in pSjS [86]. BAFF production and its mRNA expression
by cultured human minor salivary gland (HSG) epithelial
cells obtained from pSjS patients can be upregulated after
stimulation by chemical TRLs agonist (Poly I:C) or viruses
such as reovirus type1 through pathways dependent on Toll-
like receptors (TRLs) and independent of type I IFN [86].
Moreover, in systemic autoimmune diseases such as SLE
environmental factors (e.g., viral infections), and apoptotic
bodies and immune complexes stimulate pDCs through
coengagement of the TLRs and Fcγ receptor, resulting in
the production of type I IFN from pDCs. Thereafter, type
I IFN induces the generation of immunogenic mature DCs,
resulting in suppression of regulatory T (Treg) cell function,
which maintain self-tolerance [87, 88].
Alternatively, TLR3 activation associated with type I IFN
upregulation led to rapid onset and reversible hyposalivation
without glandular inﬂammation [89], suggesting that sali-
vary gland dysfunction may precede autoimmunity develop-
ment or represent a separate process in the pathogenesis of
SjS. It is reported using global gene expression proﬁling that
locally produced IFN-α is detected at higher levels in acini
and endothelial cells compared with controls, but IFN-α is
mainly secreted by pDCs, which are found in the salivary
glandsofpSjSpatientsbutnotinhealthycontrols[90].Thus,
IFN-αincirculationinpSjSisargued,sinceserumIFN-αwas
detected in very few people with pSjS [55, 91, 92], suggesting
increased IFN-α was believed to be a local phenomenon.
However, systemic activity of type 1 IFN was demonstrated
using peripheral monocytes from pSjS in whichseveral genes
associated with IFN exposure were demonstrated, and serum
from patients had an enhanced capacity of inducing those
genes in the monocytic cell line, suggesting type 1 IFN activ-
ity is not only a local but also a systemic phenomenon and
pDC may be a possible source of type 1 IFN in pDC [55, 93].
Interferon regulatory factor 5(IRF5) and signal transducer
and activator of transcription 4 (STAT4) gene polymor-
phisms in the activation of type I IFN and stimulation of
innateimmunityinmiceresultedindryness,whichpreceded
inﬂammation in salivary glands, have been reported [94]. In
addition, EBV can lead to innate immunity before the devel-
opment of autoimmune epithelitis in animal models [87]. If
that is the case, there is a possibility that circulating type I
IFN in SjS mayaﬀectfunction of lacrimal and salivaryglands
before the development of inﬂammation of those organs.
3.4. Complement. Complements may play an important role
inacquiredimmunityinSjSpathogenesis.Alsocomplements
may mediate innate immunity and contribute to pathogen-
esis of nonimmunologic phases, although their roles are not
well investigated in SjS.
SjS patients with systemic extraepithelial manifestations
display low serum levels of the complement component
C4 [95]. We have reported [96] the presence of IgG2a
and C3 in basement membranes at inﬂamed areas but also
at noninﬂamed areas in submandibular glands of B/WF1
mice, suggesting those may aﬀect the function of those
organs. Nguyen et al. [97] reported that inactivation of C3
(elimination of the C3 gene) in the parental C57BL/6.NOD-
Aec1Aec2 strain, a congenic strain of the NOD model,
resulted in a diminished or total absence of both preclinical
and clinical manifestations during the development and
onset of disease, including reduced acinar cell apoptosis,
reduced levels of caspase-3, lack of leukocyte inﬁltration
of submandibular glands, reduced synthesis of disease-
associated autoantibodies, maintenance of normal glandular
architecture, and retention of normal saliva secretion. In
addition, C57BL/6.NOD-Aec1Aec2.C3(−/−) mice, which is
the C3 gene knockout mice, retained some early patholog-
ical manifestations, including activation of serine kinases
with proteolytic activity for parotid secretory protein. This
improvement in the clinical manifestations of SjS-like dis-
ease in C57BL/6.NOD-Aec1Aec2.C3(−/−) mice, apparently
a direct consequence of C3 deﬁciency, supports a much
moreimportantroleforcomplementintheadaptiveautoim-
mune response than previously recognized, possibly also
implicating an essential role for innate immunity. Thus,
they suggest that C3 can play an equally important role
in human SjS disease before onset of clinical disease. The
role of compliment components in SjS especially during the
preimmune phase related with their injurious actions on
components of lacrimal and lacrimal and salivary glands has
to be investigated,
3.5. Cytokine. If basic diseases in sSjS precede dacryoadenitis
and sialoadenitis, circulating proinﬂammatory and inﬂam-
matory cytokines as a consequence of immune reactions
may reach at target organs and they may aﬀect functions
of those organs (e.g., capillary, myoepithelium, nervous
system, tight junction, and basement membrane) before
the development of immune reactions at the local sites.
If that is the case, capillary and venular endothelium
dysfunction with alteration of basement membranes may
lead to the leak of those cytokines from the circulation
into the target organs (Figure 1). Thus, in this section, the8 Journal of Biomedicine and Biotechnology
role of proinﬂammatory cytokines including inﬂammatory
cytokines in SjS pathogenesis will be introduced.
In general, cytokines play a central role in the regulation
of immunity and are often found to be dysregulated in SjS
[98]. Roescher et al. [99] reviewed that in the salivary glands,
saliva, and serum of these patients many proinﬂammatory
cytokines such as IFNs, IL-12, IL-18, TNF-α,I L - 1 β,I L - 6 ,
and B-cell activating factor are upregulated, whereas anti-
inﬂammatory cytokines such as transforming growth factor
(TGF)β1 are undetectable or are expressed at relatively
low levels in SjS, except for IL-10 in SjS. Baturone et al.
[100] reported that patients with pSjS showed signiﬁcantly
increased concentrations of each of the ﬁve cytokines (IL-1β,
IL-6, IL-10, TNF-α,a n dI F N - γ) in serum, when compared
with the healthy control group, indicating the existence of
an immune activation state. Serum levels of one of these
cytokines, IL-6, were correlated with poor quality of life in
these individuals. Willeke et al. [101] reported that the num-
ber of TNF-α and IL-1β, but not IL-6, secreting peripheral
blood mononuclear cells (PBMCs) was signiﬁcantly higher
inpatientswithpSjSthanincontrols.Patientswithrecurrent
parotid swelling (RPS) had a signiﬁcantly increased number
of IL-1β-secreting PBMCs. Moreover, the number of IL-1β-
secreting PBMCs correlated with the disease activity with
the increased concentration of IgM rheumatoid factor (RF)
and IgG RF. Other autoantibodies did not correlate with
cytokine secreting PBMCs. The increased systemic secretion
of IL-1β and TNF-α in patients with pSjS points to a
pathogenic impact of these cytokines in this autoimmune
disease. In particular, the correlation of IL-1β-secreting
PBMCs with RPS and RF production indicates that IL-1β is
a crucial regulator in the development of local and systemic
disease manifestations. Solomon et al. [102] reported that
proinﬂammatory cytokines in tears are derived from local
and systemic origin as follows. Compared with normal
subjects, the concentration of IL-1 α and mature IL-1 β in
the tear ﬂuid was increased, in patients with SjS aqueous tear
deﬁciency. The activity of matrix metalloproteinase (MMP)-
9, a physiological activator of IL-1, was signiﬁcantly elevated
in the tear ﬂuid compared with normal subjects. Dry eye
disease (rosacea-associated meibomian gland disease and
SjS) is accompanied by an increase in the proinﬂammatory
forms of IL-1 (IL-1α and mature IL-1β)a n dad e c r e a s e
in the biologically inactive precursor IL-1β in tear ﬂuid.
Increased protease activity on the ocular surface may be
one of mechanisms by which precursor IL-1β is cleaved
to the mature, biologically active form. The conjunctival
epithelium appears to be one source of the increased
concentration of IL-1 in the tear ﬂuid of patients with
dry eye disease. These results suggest that IL-1 may play a
key role in the pathogenesis of keratoconjunctivitis sicca.
Both biological active factors may aﬀect the function of
components in local target organs. Jabs et al. [103]r e p o r t e d
that mRNAs for inducible nitric oxide synthase iNOS and
TNF-α were detected in the lacrimal glands in signiﬁcantly
greater amounts in both MRL/+ and MRL/lpr mice than in
normal BALB/c mice. Both iNOS and TNF-α were detected
in normal acinar tissue other than in scattered mononuclear
cells throughout the lacrimal glands and in mononuclear
cells at the junction of the focal inﬂammatory inﬁltrates in
both MRL/+ and MRL/lpr mice, suggesting that both NO
and TNF-α are potential mediators of lacrimal gland damage
in these murine models of SjS. Li et al. [104] reported that
cathepsin H (Ctsh), S (Ctss), and Z (Ctsz) and proinﬂam-
matory factors (TNF-α,I L - 6 ,I L - 1 β) were upregulated at the
mRNA level in lacrimal glands of male NOD mice. Increased
cathepsin S immunoﬂuorescence was detected in lysosomes
and secretory vesicle-like organelles in lacrimal gland acinar
cells and CD68-positive inﬁltrating macrophages in NOD
mouse lacrimal gland. Cathepsin S (CATS) and cathepsin H
(CATH) activities were signiﬁcantly higher in lacrimal gland
lysate from NOD mouse than in control lysate, and CATS
activity was also signiﬁcantly elevated in tears of NOD mice.
These suggest that expression of CATS and CATH increases
in parallel with proinﬂammatory cytokines during the devel-
opment of autoimmune inﬂammatory disease in NOD mice.
Alternatively, human salivary gland cells can be induced
to express HLA-DR mRNA along with other inﬂammatory
cytokine gene expression such as IL-1β,T N F - α, and IL-6,
followingstimulationwithIFN-γ [105].Furthermore,IFN-γ
is able to upregulate B7.1, B7.2, and HLA-DR expression in
salivary gland epithelial cell lines from SjS patients [32, 106].
These suggest a possible involvement of IFN-γ in triggering
the epithelial pathology of salivary gland at a preclinical,
asymptomatic phase in NOD mice, and active participation
of epithelial cells in the disease process occurs through the
expression or upregulation of co-stimulatory molecules for
the presentation of antigen to the T-cell or through the up-
regulation of apoptotic molecules such as FasL to induce
apoptosis in the diseased glands. In B/WF1 mice glomeru-
lonephritis precedes lacrimation and sialoadenitis [107–110]
(Figures 1 and 2). Before and during the developmental
phase of glomerulonephritis, proinﬂammatory (e.g., IL-1α,
IL-6, and less amounts of TNF-α) and inﬂammatory (e.g.,
IFN-γ) cytokines are circulating in the blood [101–109].
Yamakawa et al. [111] reported that IL-1β,T N F - α,a n dI L -
6 have been implicated in the destruction of parotid gland
acinar cells (but not duct cells) in autoimmune sialoadenitis.
Yao et al. [112] reported that the intraperitoneal injection of
lipopolysaccharide (LPS) induced the expression of mRNAs
of IL-1β,I L - 6 ,a n dT N F - α in the submandibular gland of
C3H/HeN mice but not that of C3H/HeJ mice, a mutant
strain for lacking of Toll-like receptor-4 (TLR-4(−) mutant).
The mRNA levels of these cytokines in the submandibular
glands of the wild-type mice increased as early as 3 hr
after injection, peaked at 3–6hr, and had decreased again by
24hr. Denervation of the superior cervical trunk and chorda
tympani nerve did not diminish the LPS-induced elevation
of IL-1β mRNA in the SMG, indicating the irrelevance of the
central nervous system in this induction. IL-1β proteins were
localized in the secretory granules of granular convoluted
tubular (GCT) cells in the submandibular gland, and IL-1β
ofthesamesizeappearedinthesaliva6hrafterLPSinjection
in C3H/HeN but not in C3H/HeJ mice. Also, the amount
of IL-1β protein is upregulated in acinar cells prepared from
lacrimal glands inﬁltrated with lymphocytes, suggesting that
elevated levels of IL-1β, as they occur in SjS exocrine glands,
may impair the secretory function of lacrimal glands.Journal of Biomedicine and Biotechnology 9
Cytokines especially proinﬂammatory cytokines may be
involved in dysfunction of salivary and lacrimal glands by
directly interfering with the epithelial cells in the glands dur-
ing the phase of noninﬂammation other than autoimmune
reaction. Moreover, it has been reported that, cytokines in
the circulation may aﬀect the function of epithelial cells
[113] ,w h i c hm a yb er e l a t e dw i t hd e c r e a s e dt e a r sa n ds a l i v a
before the development of dacryoadenitis and sialoadenitis.
Taken together, production of cytokines may aﬀect function
of those organs during the noninﬂammatory phases in sSjS,
including even in pSjS with lesions of exocrine organs in the
immune phase.
3.6. Autonomic Nerve. The functional impairment of
exocrine glands could be regulated by cytokines and/or
antibodies against the muscarinic M3 receptor by inhibiting
the neural stimulation of the residual glands as described
already. Autonomic nervous system (ANS) abnormalities are
common in Sj¨ ogren’s syndrome in the immune reaction
[114–117] and may play an etiologic role in its pathogenesis.
Fatigue, another prominent feature of SjS, has also been
associated with ANS dysfunction [118].
The complexity of the ANS along with diﬀerences
in methodology and studied populations has resulted in
variable results, but abnormalities in SjS have been reported
bothinsympatheticandparasympatheticANSdomainswith
prevalenceashighas90%[114].Zoukhrietal.foundthatthe
lymphocytic inﬁltration of the lacrimal and salivary glands
did not alter the parasympathetic, sympathetic, and sensory
innervation of the remaining epithelial cells in these tissues
in model mice [119]. Barendregt et al. [118]h a v ec o n ﬁ r m e d
the presence of cardiovascular autonomic abnormalities and
identiﬁed a cluster of subjective autonomic self-reported
symptoms associated with fatigue and salivary gland dys-
function. The functional impairment of exocrine glands
could be regulated by antibodies against the muscarinic
M3 receptor by inhibiting the neuronal stimulation of
the residual glands [120] including the possible eﬀects of
cytokines in both pSjS and pSjS. Taking a consideration of
decreased vascular responses to salivary gland stimulation in
SjS patients, Berggreen et al. [121] demonstrated maximal
blood ﬂow responses to parasympathetic stimulation and
muscarinic receptor activation were signiﬁcantly lower in
NOD mice compared with BALB/c mice, coinciding with
impaired saliva secretion in NOD mice, and reduced nitric
oxide signaling after parasympathetic nerve stimulation may
contribute in part to the impaired blood ﬂow responses.
Pedersen et al. [122] reported that the hyposalivation
observed in NOD mice may, at least in part, be due to a
general loss of neurotransmitter responsiveness in salivary
glands. This important ﬁnding suggests that genetic defects
may be responsible for decrease in saliva production other
than destruction of salivary glands by immunologic attacks.
Impaired neurotransmitter release in salivary glands in the
MRL/lpr mouse has also been reported [123]. In addition,
patients with SjS have elevated salivary levels of vasoac-
tive intestinal peptide (VIP) and neuropeptide Y (NPY),
which are mainly found in parasympathetic and sympa-
thetic nerves, respectively. This ﬁnding indicates increased
release of VIP and NPY by salivary glands of SjS patients
[124].
Humphreys-Beheretal.[125] reported thattearand sali-
vary ﬂow involves an entire functional system that includes
themucosalsurfaceswithadnexes(thesiteofinﬂammation),
eﬀerent nerve signals sent to the midbrain (lacrimal and
salivary response region), and aﬀerent neural signals from
the brain to the acinar/ductal epithelial structures in the
gland. In addition, the electron-microscopic examinations
showed that the nerve ﬁbres were in close association to the
secretory cells, to the smooth muscle cells of blood vessels,
and to the immuno-competent cells. Among several possible
extraglandular manifestations, involvement of the peripheral
nervous system may occur with reported frequencies from
10% to 60% in pSjS [126]. Regarding the role of circulating
cytokines, Zoukhri et al. [113] reported that proinﬂamma-
tory cytokines such as recombinant human (rh) IL-1 α,
rhIL-1β,a n dr h T N F - α inhibit neurally mediated lacrimal
gland secretion in normal BALB/c mice in vitro and in vivo,
suggesting there can be various extraglandular complication.
Taken together, circulating cytokines in sSjS before the devel-
opment of inﬂammation may aﬀect extraglandular nervous
system other than function of lacrimal and salivary glands.
3.7. Tight Junction. The components of tight junction (Tj)
such as ZO-1 and occluding are involved in the pathogenesis
in SjS, and cytokines may aﬀect not only in their expression
but also in morphological changes. Cytokines inﬂuence
the function and morphology of tight junction of acinus
epithelial cells in the process of inﬂammation. If that is the
case, changes of tight junction will be induced during the
noninﬂammatory phase in SjS especially in sSjS.
Ewert et al. [127] reported signiﬁcant diﬀerences in tight
junction protein levels in patients with SjS in relation with
proinﬂammatory cytokines as follows. ZO-1 and occludin
were strongly downregulated, while claudin-1 and claudin-
4 were overexpressed in SjS and tight junction proteins
localized exclusively to apical domains in acini and ducts of
labial salivary glands (LSGs) from controls. In SjS patients,
the ZO-1 and occludin the apical domain presence was
decreased, while claudin-3 and claudin-4 were redistributed
to the basolateral plasma membrane. Exposure of isolated
control acini to TNF-α and IFN-γ reproduced these alter-
ations in vitro. Moreover, ultrastructural analysis associated
tight junction disorganization with the presence of endo-
cytic vesicles containing electron-dense material that may
representtightjunctioncomponents.Theyindicatethatlocal
cytokineproductioninlargesalivaryglandsfromSjSpatients
may contribute to the secretory gland dysfunction observed
inSjSpatientsbyalteringtightjunctionintegrityofepithelial
cells, thereby decreasing the quality and quantity of saliva.
Baker et al. [128] reported that the production of the
proinﬂammatorycytokines(TNF-αandIFN-γ)iselevatedin
exocrine glands of patients with SjS in which chronic expo-
sure of polarized rat parotid gland (Par-C10) epithelial cell
monolayers to TNF-α and IFN-γ decreases transepithelial
resistance (TER) and anion secretion. Treatment of Par-C10
cell monolayers with TNF-α and IFN-γ increased paracellu-
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cell and TJ morphology, and downregulated the expression
of the TJ protein, claudin-1, but not other TJ proteins
expressed in Par-C10 cells. They also suggest that cytokine
productionisanimportantcontributortosecretorydysfunc-
tion in SjS by disrupting TJ integrity of salivary epithelium.
3.8. Basement Membrane. The situation of basement mem-
brane (BM) in terms of functional and morphologic changes
may be similar to that of tight junction.
Molinaetal.[129]reportedthechangesintheexpression
of laminin and type IV collagen in the basement membrane
of acini and ducts of labial salivary glands from patients
with SjS were more pronounced than in labial salivary glands
from control groups. A remarkable characteristic was the
disorganization of the basement membrane in the labial
salivaryglandsinSjS.Thepatternofimmunoreactivityofthe
basement membrane of other structures (e.g., blood vessels)
did not change and invasion of cytotoxic T lymphocytes was
only observed in acini and ducts which had a disorganised
basement membrane. They concluded that the high state
of disorganization of the basal lamina of acini and ducts
could allow invasion of cytotoxic T lymphocytes in SjS. This
suggests that the changes of basement membranes are the
result of immune attack.
On the other hand, preceded changes of the basement
membrane (e.g., collagen type IV, proteoglycan, and ﬁbrone-
ctin) in the pathogenesis of the inﬂammation has been
demonstrated by McArthur et al. [130]. They demonstrated
that the potential roles of the basement membrane proteins,
laminin and ﬁbronectin, and the cytoskeletal protein, tubu-
lin, were assessed in the pathogenesis of SjS by comparing
their expressions in SjS with normal labial salivary gland
tissue. An increase in laminin or a laminin-like substance on
salivary ductal epithelia of SjS patients suggests a potential
role for laminin in the pathologic mechanism and increased
laminin expression as a marker for SjS. The importance
of their ﬁndings is that expression of components of the
basement membrane precedes the immunological events
in salivary glands. We reported [131] laminin expression
around the ducts was signiﬁcantly higher in young B/WF1
mice than that in control (BALB/c and DBA/1) mice.
Periductal laminin expression increased in B/WF1 mice with
age. In addition vary late antigen (VLA)-6, which is a ligand
for laminin, was expressed by the inﬁltrating cells. These
suggest that precede laminin expression may be responsible
for cell inﬁltration of the submandibular salivary gland
other than immune attack. Deﬁlippi et al. [132]r e p o r t e d
TNF-α and IL-1 down regulate laminin receptor, suggesting
that proinﬂammatory cytokines may aﬀect laminin receptor
expression before the development of inﬂammation in SjS.
In addition, the acinar basement membrane is abnormal
as it lacks laminin α1, α2a n dα4 chains and lack of alpha 1,
whichmayimpairitscapabilitytoinducetheprogenitorcells
to diﬀerentiate to acinar cells, leading to leading to acinar
cell atrophy and ductal cell hyperplasia [19]. Lamininα1-
chain normally induces intercalated duct progenitors to
diﬀerentiate to acinar cells through integrin α1ss1 and α2ss1
receptors, and maintenance of acinar cells is impaired in SjS,
whichisalsocharacterizedbylowlevelsofserumandsalivary
androgens, since androgens normally support salivary gland
remodeling by upregulating either laminin α1 chain or its
cellularα1o r α2 integrin subunit-containing receptors [133].
Sullivan et al. [134] demonstrated that the meibomian gland
is an androgen target organ and that androgen deﬁciency
may promote meibomian gland dysfunction and evaporative
dry eye, suggesting that androgen deﬁciency may be an
important etiologic factor in the pathogenesis of evaporative
dry eye in women with SjS. As one of these mechanisms,
androgen deﬁciency may be the eﬀect on laminin [133].
Taking together, at ﬁrst circulating cytokines may aﬀect
morphological and functional changes of the BM, and
secondly those changes may permit the leak of circulating
several humoral factors including cytokines from capillaries
by increased permeability. Furthermore, leaked cytokines
may aﬀect function of salivary and lacrimal glands (Figures
1–3). In addition, dysfunction of BM by immune attacks
seems likely [96].
4. Conclusions
The pathogenesis of SjS remains elusive. Environmental,
genetic, and hormonal factors may be involved in its patho-
genesis (especially as the role of trigger), and in the past,
researchers have focused on the immune responses especially
T cell-mediated and humoral immunities in the histopatho-
logical lesion during the inﬂammatory phase of SjS [135].
The key question in this review is nonimmune mechanisms
relating to dysfunction of lacrimal and salivary glands
before the development of acquired immunity. Regard-
ing nonimmune mechanisms, apoptosis/nonapoptosis and
abnormal expression/distribution of AQPs may be, at least
in part, induced genetically. Alternatively, it has been sug-
gested that genetic defect in production of neurotransmitter
may underlay in the pathogenesis of saliva insuﬃciency
[122]. In addition, exogenous environmental factors (viruses
and bacteria) may activate innate immunity, resulting in
productions of type I IFN and compliments. Circulating
proinﬂammatorycytokinesmayinducenotonlydysfunction
but also morphological changes at the ultrastructural level of
autonomic nerve, tight junction, and basement membrane.
The cumulative eﬀects of each factor/change may induce
decreased function of lacrimal and salivary glands without
inﬂammation. Regarding this point, this review stressed the
importance of changes in microenvironments (niche) [136]
within target organs before the inﬂammatory cell inﬁltration
in sSjS, including even in pSjS with exocrinopathy.
To clarify the pathogenesis of SjS using animal models
is useful as reviewed previously [31]. However, as described
here numerous diﬀerences exist between mice and humans
(the species diﬀerence) that suggest mouse studies are not
always applicable to human disease. For example, female
MRL/lpr, B/WF1,N F S / s l d ,a sI Q I / j i ca n daly/aly mice and
NOD mice have been studied as the most notable animal
models for their resemblance to autoimmune connective
tissue diseases[31]. All of these mice show immunological
characteristics in common with SjS (e.g., hypergammaglob-
ulinemia, polyclonal B-cell activation, autoantibody produc-
tion, and mononuclear cell inﬁltration in the lacrimal andJournal of Biomedicine and Biotechnology 11
salivary glands). Despite heavy inﬁltrates within the glands,
keratoconjunctivitis sicca (dry eyes) and xerostomia (dry
mouth),whicharethehallmarksofSjSinhumans,havebeen
observed in NOD mice, but not MRL/lpr mice [31]. On the
other hand, the loss of secretory function at the age of 6
months of age in B/WF1 mice occur. Concerning NFS/sld
mice, secretory dysfunction was observed at 18 months of
age, but this may be relating with age. Moreover, functional
d e f e c to fo t h e rm o d e l ss u c ha sI Q I / j i ca n daly/aly mice is
not known. These suggest that mouse age and strain used in
experiments are an important factor for functional analysis.
In addition, the reasons of contradictory results even within
the same strain of mice with the same genetic background
such as NOD mice are not known. Alternatively, there are
morphological and functional diﬀerences between salivary
and lacrimal glands, between mouse and human, or between
salivary glands. Moreover, anesthesia in the examination of
lacrimal and salivary glands function in mice, but not in
human, may aﬀect the function of those organs. However,
these did not deny the usefulness of mouse model, but I
would like to stress that extrapolation of the results of the
mouse studies to human in autoimmune SjS must be done
with caution in each mouse model.
The causes of hypofunction in salivary and lacrimal
glands are complex. The future challenge is to distinguish
nonimmunologic mechanisms from immunologic mecha-
nisms in target organs in this unique disease. Identiﬁcation
of gene(s) being responsible for nonimmune pathogenesis
using gene targeting models is another way [65]. To create an
integrated model that can account for salivary and lacrimal
glands hypofunction is ideal [66].
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